Q-omics provides the consensus-scored LAMTOR4 profile across patient tissues and cancer cell-line models. LAMTOR4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LAMTOR4 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, LAMTOR4 RNA expression shows 19,512 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, KIRC, and THYM as cancer lineages where LAMTOR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LAMTOR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LAMTOR4 survival associations across molecular data types. LAMTOR4 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LAMTOR4 RNA expression–survival associations across cancer types. High LAMTOR4 expression shows unfavorable associations in KICH, UVM, COAD, LIHC, ACC and LGG. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for LAMTOR4 RNA expression.
This table summarizes LAMTOR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LAMTOR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LAMTOR4 shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, HNSC, CHOL and KIRP. The KIRC box plot shows higher LAMTOR4 RNA expression in tumor versus normal tissue (log2 FC = +0.531, t-test p < 0.001).
This table shows molecular features associated with LAMTOR4 in patient tissues and cancer cell lines. In patient samples, LAMTOR4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LAMTOR4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OVARY.
